Try our mobile app

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Published: 2024-08-21 15:45:00 ET
<<<  go to DZSI company page

ORION CORPORATION MANAGERS’ TRANSACTIONS 21 AUGUST 2024 at 18.45 EEST        

Orion Corporation: Managers’ transactions – Niclas Lindstedt

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Niclas LindstedtPosition: Other senior managerIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 74920/9/8

____________________________________________Transaction date: 2024-08-20Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009014377Nature of transaction: DISPOSAL

Transaction details(1): Volume: 614 Unit price: 46.7 EUR (2): Volume: 521 Unit price: 46.7 EUR (3): Volume: 200 Unit price: 46.7 EUR (4): Volume: 200 Unit price: 46.7 EUR (5): Volume: 100 Unit price: 46.7 EUR (6): Volume: 125 Unit price: 46.7 EUR (7): Volume: 100 Unit price: 46.7 EUR (8): Volume: 125 Unit price: 46.7 EUR (9): Volume: 8 Unit price: 46.7 EUR (10): Volume: 5 Unit price: 46.7 EUR (11): Volume: 2 Unit price: 46.7 EUR

Aggregated transactions (11): Volume: 2000 Volume weighted average price: 46.7 EUR

Orion Corporation

Liisa HurmePresident and CEO   Olli HuotariSVP, Corporate Functions 

                                                

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.